13th PVRI Annual World Congress, Barcelona, İspanya, 31 Ocak - 02 Şubat 2019, ss.10
Introduction
• Pulmonary endarterectomy (PEA) is the treatment of
choice for patients with CTEPH as it is potentially curative.1
However, in non-operable patients or in the presence
of persistent/recurrent CTEPH after surgery, the soluble
guanylate cyclase (sGC) stimulator riociguat is the only
recommended and approved targeted medical treatment
in EMEA countries.1–3
–– Therapies licensed for the treatment of pulmonary arterial
hypertension (PAH) are also often prescribed off-label.4
• While the diagnosis and management of CTEPH have been
assessed in registries in Canada, Western/Central European
countries, and the USA,5–9 there are no available data for
relevant Eastern European and Middle Eastern geographies.
• This CTEPH registry was initiated in Kazakhstan, Lebanon,
Russia, Saudi Arabia, and Turkey in 2016 in order to improve
understanding of the evaluation and management of CTEPH
in these countries. Here, we report the design and baseline
demographics from this registry.